

Page 1 of 6

Instructions for this form can be accessed: <u>https://www.cdc.g</u>	ov/nhsn/forms/instr/57.137-to	i-annual-facility-survey.pdf		
*Required for saving	Tracking #:			
Facility ID:	*Survey Year:			
*National Provider ID:	State Provider #:			
Facility Characteristics				
*Ownership (check one):				
□ For profit □ Not for profit, including church	□ Government (not VA)	Veterans Affairs		
*Certification (check one):				
Dual Medicare/Medicaid Medicare only	Medicaid only	☐ State only		
*Affiliation (check one): □ Independent, free-standing	 Independent, continuing community 	g care retirement		
Multi-facility organization (chain)	i, attached 🛛 🗆 Hospital syste	em, free-standing		
In the previous calendar year: *Average daily census:				
*Total number of short-stay residents: Average length of stay for short-stay residents: *Total number of long-stay residents: Average length of stay for long-stay residents:				
*Total number of new admissions:				
*Number of Beds: *Number of Pediatric Beds (age <21): *Indicate which of the following primary service types are provided by your facility. On the day of this survey, indicate the number of residents receiving those services (list only one service type per resident, i.e. total should sum to resident census on day of survey completion):				
	Service provided? Numbe	r of residents		
a. Long-term general nursing:				
b. Long-term dementia:				
c. Skilled nursing/Short-term (subacute) rehabilitation:				
d. Long-term psychiatric (non-dementia):				
e. Ventilator:				
f. Bariatric:				
g. Hospice/Palliative:				
h. Other:				
Assurance of Confidentiality: The voluntarily provided information obtained in this surv collected with a guarantee that it will be held in strict confidence, will be used only for th consent of the individual, or the institution in accordance with Sections 304, 306 and 30	e purposes stated, and will not otherwise	be disclosed or released without the		

Public reporting burden of this collection of information is estimated to average 135 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333, ATTN: PRA (0920-0666).

CDC 57.137 Rev 13.0 Release - January 2025

Continued >>



Page 2 of 6		
Facility Microbiology Laboratory Practices *1. Does your facility have its own laboratory that performs microbiology	ogy/antimicrobial susceptibility testing?	
\Box Yes \Box No		
If No, where is your facility's antimicrobial susceptibility testing	g performed? (check one)	
\Box Affiliated medical center, within same health sy	stem	
Commercial referral laboratory		
*2. Indicate whether your facility screens new admissions for any of t (MDROs): (check all that apply)	he following multidrug-resistant organisms	
We do not screen new admissions for MDROs		
 Methicillin-resistant Staphylococcus aureus (MRSA) If checked, indicate the specimen types sent for screenir 	ng: (check all that apply)	
□ Nasal swabs □ Wound swabs □	□ Sputum □ Other skin site	
 Vancomycin-resistant <i>Enterococcus</i> (VRE) If checked, indicate the specimen types sent for screenir 	ng: (check all that apply)	
□ Rectal swabs □ Wound swabs	□ Urine	
 Multidrug-resistant gram-negative rods (includes carbapen resistant Acinetobacter, etc.) If checked, indicate the specimen types sent for screenir 		
□ Rectal swabs □ Wound swabs □	□ Sputum □ Urine	
 Candida Auris (C. Auris) If checked, indicate the specimen types sent for screening Skin Nares Other 		
□ Skin		
*3. What is the primary testing method for <i>C. difficile</i> used most often laboratory where your facility's testing is performed? (check one		
Enzyme immunoassay (EIA) for toxin	□ GDH plus NAAT (2-step algorithm)	
□ Cell cytotoxicity neutralization assay	□ GDH plus EIA for toxin, followed by NAAT for discrepant results	
□ Nucleic acid amplification test (NAAT) (e.g., PCR, LAMP)	 Culture (<i>C. difficile</i> culture followed by detection of toxins) 	
□ NAAT plus EIA, if NAAT positive (2-step algorithm)	□ Other (specify):	
 Glutamate dehydrogenase (GDH) antigen plus EIA for toxin (2-step algorithm) 		
("Other" should not be used to name specific laboratories, reference laborator methods can be categorized accurately by selecting from the options provide Instructions for this form, or conduct a search for further guidance on selecting	ed. Please ask your laboratory, refer to the Tables of	
*4. Does your laboratory provide a report summarizing the percent of identified in cultures sent from your facility (often called an antibio		
Yes No		
If Yes, how often is this summary report or antibiogram provided	to your facility? (check one)	
□ Once a year □ Every 2 years □	□ Other (specify):	
CDC 57.137 Rev 13.0 Release – January 2025	Continued >>	



Page 3 of 6
Infection Prevention and Control Practices *5. In addition to the Infection Preventionist (IP) role, how many other roles is the IP responsible
for? Select all that apply:
Director of Nursing
Assisted Director of Nursing
Floor Nurse (clinical)
□ Administrator
□ Other
*6. What formal training has your Infection Preventionist received? Select all that apply:
□ None
Infection Prevention Training Course through CDC
Infection Prevention Training Course through State Health Department
□ Other
*7. What certification has your infection preventionist obtained? Select all that apply:
Certification in Infection Control (CIC)
Long-Term Care Certification in Infection Prevention (LTC-CIP)
□ Other
*8. How many times in the past year have you had to find a new employee to take over the Infection Preventionist (IP) role? In other words, how many times has this position "turned over"? (check one)
Did not turn over the IP role in the past year
Once
Four or more
*9. Total infection preventionist hours per week dedicated to infection prevention and control activity in facility:
a. Total hours per week performing surveillance:
b. Total hours per week for infection prevention and control activities other than surveillance:
*10. Is it a policy in your facility to routinely use gown/gloves for care of residents infected or colonized with a
multidrug-resistant organism (MDRO)? □ Yes □ No (<i>If "No", continue to question 11</i>) CDC 57.137 Rev 13.0 Release – January 2025



If yes, please select the option that is applicable to your facility for each MDRO. ("No" should only be selected if your facility does not have a policy for the MDRO listed.)

<u>Multidrug-resistant organism (MDRO)</u>	<u>All infected or</u> colonized with?	<u>Certain characteristics</u> <u>that make them high</u> <u>risk for transmission</u> (e.g., wounds, <u>presence of an</u> <u>indwelling device</u>	<u>No</u>	
a. MRSA:				
b. VRE:				
c. CRE: d. ESBL or extended spectrum				
cephalosporin resistant Enterobacteriaceae				
Novel and/or CDC-targeted MDROs				
e. Pan-resistant organisms				
f. Carbapenemase-producing organisms (e.g., Carbapenemase- producing Enterobacterales)				
g. Candida auris				
 *11. Is it a policy in your facility to use gowns/gloves for care of residents with certain characteristics that make them high-risk for transmission or acquisition of an MDRO (e.g., wounds, presence of an indwelling device) regardless of MDRO status? *12. When a resident colonized or infected with an MDRO is transferred to another facility, does your facility 				
communicate the resident's MDRO status to the receiving facility at the time of transfer? $\hfill \Box$ Yes \Box No				
*13. Among residents with an MDRO admitted to percentage of the time does your facility rec the resident's MDRO status?			%	



Page 4 of 6				
Antibiotic Stewardship Practices				
*14. Are there one or more individuals responsil antimicrobials at your facility?	ole for the impact of ac	tivities to improve use of	□ Yes	□ No
If Yes, what is the position of the individ	ual(s)? (select all that a	apply)		
□ Medical director □ Dir	ector of Nursing	Infection Preventior	nist	
□ Consultant Pharmacist □ Oth	er (please specify):	······		
*15. Does your facility have a policy that requires prescribers to document an indication for all antimicrobials in the medical record or during order entry?			□ Yes	□ No
If Yes, has adherence to the policy to document an indication been monitored?		□ Yes	🗆 No	
*16. Does your facility provide treatment recomm national guidelines to assist with antimicrol		n infections based on	□ Yes	□ No
If Yes, has adherence to facility-specific treatment recommendations been monitored?		□ Yes	□ No	
*17. Is there a formal procedure for performing a antimicrobial start to determine whether the (e.g. antibiotic time out)?			□ Yes	🗆 No
*18. Is there a formal procedure for reviewing courses of antimicrobial therapy and communicating with prescribers on antimicrobial selection, dosing, or duration of therapy (i.e., audit and feedback) at your facility?			□ Yes	🗆 No
*19.Does your facility have a system for tracking	g antimicrobial use?			
If yes, what is the source of the antimic	obial use report provid	led?	□ Yes	🗆 No
□ Pharmacy services	Electro	onic Health Records		
☐ Manual reporting (i.e., facility infection c	ontrol log) 🛛 Other	(please specify):		
*20. Has your facility provided education to clinicians and other facility staff on improving antimicrobial use in the past 12 months?		□ Yes	□ No	
*21. Does your facility have a written statement of support from leadership that supports efforts to improve antimicrobial use?		□ Yes	□ No	
			Con	tinued >>



Antibiotic Stewardship Practices (continued) *22. Are antimicrobial use and resistance data reviewed by leadership in quality assurance/performance improvement committee meetings? □ Yes □ No *23. Does your facility have access to individual(s) with antimicrobial stewardship expertise (e.g., consultant pharmacist trained in antimicrobial stewardship, stewardship team at referral hospital, external infectious disease/stewardship consultant)? □ Yes □ No Electronic Health Record Utilization *24. Indicate whether any of the following are available in an electronic health record (check all that apply): □ Microbiology lab culture and antimicrobial susceptibility results □ Medication orders □ Medication administration record □ Resident vital signs □ Resident progress notes □ Resident transfer or discharge notes □ None of the above ■ 25. Have you ever conducted a facility risk assessment to identify where Legionella and other opportunistic waterborne pathogens (e.g., <i>Pseudomonas, Acinetobacter, Burkholderia, Stenotrophomonas</i> , nontuberculous mycobacteria, and fungi) could grow and spread in the facility water system (e.g., piping infrastructure)? □ Yes □ No □ S 1 year ago □ >1 and ≤ 3 years ago □ >1 and ≤ 3 years ago				
assurance/performance improvement committee meetings? □ Yes □ No *23. Does your facility have access to individual(s) with antimicrobial stewardship expertise (e.g., consultant pharmacist trained in antimicrobial stewardship, stewardship team at referral or Yes □ No hospital, external infectious disease/stewardship consultant)? □ Yes □ No Electronic Health Record Utilization □ Yes □ No *24. Indicate whether any of the following are available in an electronic health record (check all that apply): □ Microbiology lab culture and antimicrobial susceptibility results □ Medication orders □ Medication administration record □ Resident vital signs □ Resident progress notes □ Resident transfer or discharge notes □ Resident transfer or discharge notes □ None of the above ■ No 25. Have you ever conducted a facility risk assessment to identify where Legionella and other opportunistic waterborne pathogens (e.g. Pseudomonas, Acinetobacter, Burkholderia, Stenotrophomonas, nontuberculous mycobacteria, and fungi) could grow and spread in the facility water system (e.g., piping infrastructure)? □ Yes □ No □ Yes, when was the most recent assessment conducted? (Check one) □ >1 and ≤ 3 years ago □ >1 and ≤ 3 years ago				
consultant pharmacist trained in antimicrobial stewardship, stewardship team at referral hospital, external infectious disease/stewardship consultant)? □ Yes □ No Electronic Health Record Utilization *24. Indicate whether any of the following are available in an electronic health record (check all that apply): □ Microbiology lab culture and antimicrobial susceptibility results □ Medication administration record □ Resident vital signs □ Resident admission notes □ Resident progress notes □ Resident transfer or discharge notes □ None of the above Facility Water Management and Monitoring Program 25. Have you ever conducted a facility risk assessment to identify where Legionella and other opportunistic waterborne pathogens (e.g. Pseudomonas, Acinetobacter, Burkholderia, Stenotrophomonas, nontuberculous mycobacteria, and fungi) could grow and spread in the facility water system (e.g., piping infrastructure)? If Yes, when was the most recent assessment conducted? (Check one) □ ≤ 1 year ago □ >1 and ≤ 3 years ago				
 *24. Indicate whether any of the following are available in an <u>electronic health record</u> (check all that apply): Microbiology lab culture and antimicrobial susceptibility results Medication orders Medication administration record Resident vital signs Resident admission notes Resident transfer or discharge notes None of the above Facility Water Management and Monitoring Program 25. Have you ever conducted a facility risk assessment to identify where <i>Legionella</i> and other opportunistic waterborne pathogens (e.g. <i>Pseudomonas, Acinetobacter, Burkholderia, Stenotrophomonas</i> , nontuberculous mycobacteria, and fungi) could grow and spread in the facility water system (e.g., piping infrastructure)? If Yes, when was the most recent assessment conducted? (Check one) ≤ 1 year ago >1 and ≤ 3 years ago 				
Image: Straight of the second straig				
susceptibility results □ Medication orders □ Medication administration record □ Resident vital signs □ Resident admission notes □ Resident progress notes □ Resident transfer or discharge notes □ None of the above Facility Water Management and Monitoring Program 25. Have you ever conducted a facility risk assessment to identify where Legionella and other opportunistic waterborne pathogens (e.g. Pseudomonas, Acinetobacter, Burkholderia, Stenotrophomonas, nontuberculous mycobacteria, and fungi) could grow and spread in the facility water system (e.g., piping infrastructure)? □ Yes □ No □ ≤ 1 year ago □ >1 and ≤ 3 years ago				
□ Resident admission notes □ Resident progress notes □ Resident transfer or discharge notes □ None of the above Facility Water Management and Monitoring Program 25. Have you ever conducted a facility risk assessment to identify where Legionella and other opportunistic waterborne pathogens (e.g. Pseudomonas, Acinetobacter, Burkholderia, Stenotrophomonas, nontuberculous mycobacteria, and fungi) could grow □ Yes □ No and spread in the facility water system (e.g., piping infrastructure)? If Yes, when was the most recent assessment conducted? (Check one) □ >1 and ≤ 3 years ago				
 □ Resident transfer or discharge notes □ None of the above Facility Water Management and Monitoring Program 25. Have you ever conducted a facility risk assessment to identify where Legionella and other opportunistic waterborne pathogens (e.g. Pseudomonas, Acinetobacter, Burkholderia, Stenotrophomonas, nontuberculous mycobacteria, and fungi) could grow □ Yes □ No and spread in the facility water system (e.g., piping infrastructure)? If Yes, when was the most recent assessment conducted? (Check one) □ ≤ 1 year ago □ >1 and ≤ 3 years ago 				
Facility Water Management and Monitoring Program 25. Have you ever conducted a facility risk assessment to identify where Legionella and other opportunistic waterborne pathogens (e.g. Pseudomonas, Acinetobacter, Burkholderia, Stenotrophomonas, nontuberculous mycobacteria, and fungi) could grow □ Yes □ No and spread in the facility water system (e.g., piping infrastructure)? If Yes, when was the most recent assessment conducted? (Check one) □ >1 and ≤ 3 years ago				
 25. Have you ever conducted a facility risk assessment to identify where Legionella and other opportunistic waterborne pathogens (e.g. Pseudomonas, Acinetobacter, Burkholderia, Stenotrophomonas, nontuberculous mycobacteria, and fungi) could grow □ Yes □ No and spread in the facility water system (e.g., piping infrastructure)? If Yes, when was the most recent assessment conducted? (Check one) □ ≤ 1 year ago □ >1 and ≤ 3 years ago 				
 25. Have you ever conducted a facility risk assessment to identify where Legionella and other opportunistic waterborne pathogens (e.g. Pseudomonas, Acinetobacter, Burkholderia, Stenotrophomonas, nontuberculous mycobacteria, and fungi) could grow □ Yes □ No and spread in the facility water system (e.g., piping infrastructure)? If Yes, when was the most recent assessment conducted? (Check one) □ ≤ 1 year ago □ >1 and ≤ 3 years ago 				
other opportunistic waterborne pathogens (e.g. Pseudomonas, Acinetobacter, Burkholderia, Stenotrophomonas, nontuberculous mycobacteria, and fungi) could grow □ Yes □ No and spread in the facility water system (e.g., piping infrastructure)? If Yes, when was the most recent assessment conducted? (Check one) □ ≤ 1 year ago □ >1 and ≤ 3 years ago				
\Box > 3 years ago				
26. Does your facility have a water management program to prevent the growth and □ Yes □ No transmission of <i>Legionella</i> and other opportunistic waterborne pathogens? If Yes, who is represented on the team? (Check all that apply)				
□ Facility Administrator □ Nursing Leadership □ Consultant □ Facilities Manager/ (e.g., DON or ADON) Engineer				
□ Maintenance Staff □ Infection Preventionist □ Risk/Quality □ Medical Director Management Staff				
Equipment/ Chemical Other (specify):				
27. Do you regularly monitor the following parameters in your building's water system? (Check all that apply) Disinfectant (such as residual chlorine) □ Yes □ No If Yes, do you have a plan for corrective actions when disinfectant levels are not within acceptable limits as determined by your water □ Yes □ No management program?				



Page 6 of 6	0 , , , ,			<i>,</i>	
	Temperature	□ Yes	🗆 No		
	If Yes, do you have a plan for correct temperatures are not within acceptab your water management program?			□ Yes	🗆 No
	Heterotrophic plate counts	□ Yes	🗆 No		
	If Yes, do you have a plan for correct heterotrophic plate counts are not wi determined by your water manageme	thin acceptable li		□ Yes	🗆 No
	Specific tests for Legionella	□ Yes	🗆 No		
	If Yes, do you have a plan for correct tests for <i>Legionella</i> are not within acc by your water management program	ceptable limits as		□ Yes	🗆 No